VERTEX PHARMACEUTICALS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 455.3 USD | +2.77% |
|
-0.35% | +11.91% |
| 31/05 | BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 | MT |
| 31/05 | Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing | MT |
Presenter SpeechMichael Partridge (Executives)Making prepared remarks on the call tonight, we ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
05/06/2024
- William Blair Growth Stock Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.91% | 12TCr | |
| +11.60% | 11TCr | |
| -4.68% | 2.43TCr | |
| -0.82% | 2.2TCr | |
| -10.12% | 1.82TCr | |
| -42.12% | 1.64TCr | |
| -17.47% | 1.56TCr | |
| +2.77% | 1.36TCr | |
| +34.58% | 1.23TCr | |
| +77.64% | 887.31Cr |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Transcript : Vertex Pharmaceuticals Incorporated, Q4 2020 Earnings Call, Feb 01, 2021
